|
LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC). |
|
|
Honoraria - AstraZeneca; Pfizer; Roche/Genentech |
Consulting or Advisory Role - AstraZeneca; Eisai; Merck; Pfizer; Roche |
Travel, Accommodations, Expenses - Pfizer; Roche |
|
|
Research Funding - Dongkook; Kyowa Hakko Kirin; Novartis; Sanofi |
|
|
Consulting or Advisory Role - Hanmi; Novartis; Spectrum Pharmaceuticals |
|
|
|
Research Funding - Novartis (Inst); Roche (Inst) |
|
|
Employment - Northwest Medical Specialties |
Leadership - Northwest Medical Specialties |
Speakers' Bureau - NantHealth |
Patents, Royalties, Other Intellectual Property - University of Washington (I) |
|
|
Consulting or Advisory Role - Abbvie |
Research Funding - Abbvie (Inst); Advaxis (Inst); Bayer/Onyx (Inst); Eisai (Inst); Genentech (Inst); GlaxoSmithKline (Inst); ImClone Systems (Inst); MedImmune (Inst); Merck (Inst); Nektar (Inst); Pfizer (Inst) |
Patents, Royalties, Other Intellectual Property - Tesaro (Inst) |
Travel, Accommodations, Expenses - Caris Centers of Excellence |
|
|
Consulting or Advisory Role - Abbvie; Merrimack; Myriad Genetics; PharmaMar |
Research Funding - Abbvie; Genentech; OncoPep; PharmaMar |
Travel, Accommodations, Expenses - Myriad Genetics |
|
|
Consulting or Advisory Role - Puma Biotechnology; Roche/Genentech |
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst) |
|
|
Consulting or Advisory Role - Pfizer; Puma Biotechnology; Roche |
|
|
|
Stock and Other Ownership Interests - ARIAD; Roche |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
Stock and Other Ownership Interests - Genentech |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
Leadership - Infinity Pharmaceuticals; Varian Medical Systems |
Stock and Other Ownership Interests - GRAIL; Infinity Pharmaceuticals; Juno Therapeutics; PMV Pharma; Varian Medical Systems |
Consulting or Advisory Role - Eli Lilly, Novartis; GRAIL |